CALCITRIOL INJECTION USP 1 MCG
CALCITRIOL : 1 MCG · DIN 02399334 · STERIMAX INC
Health Canada status: DORMANT
What is CALCITRIOL INJECTION USP?
CALCITRIOL INJECTION USP 1 MCG contains CALCITRIOL : 1 MCG. It is listed in the Health Canada Drug Product Database under DIN 02399334, held by STERIMAX INC, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as dormant, status dated 23-Apr-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is CALCITRIOL INJECTION USP used for?
Management of hypocalcemia in patients undergoing chronic renal dialysis; reduction of elevated parathyroid hormone (PTH) levels.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02399334 |
|---|---|
| Brand name | CALCITRIOL INJECTION USP |
| Generic / active ingredient | CALCITRIOL : 1 MCG |
| Manufacturer | STERIMAX INC |
| Strength | 1 MCG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | A11CC04 CALCITRIOL |
| AHFS class | 88:16.00 |
| Biosimilar | No |
| Health Canada status | DORMANT |
| Status date | 23-Apr-2025 |
| Original market date | 2015-03-27 00:00:00 |
How is it administered?
Initial: 0.5 mcg (0.01 mcg/kg) IV 3 times weekly, every other day. Increase by 0.25 to 0.5 mcg at 2-4 week intervals based on response. Administer as bolus at end of hemodialysis.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Store between 15°C and 30ºC. Protect from light, excessive heat, and freezing.
How is it supplied?
1 mL ampoules containing 1 mcg of calcitriol.
Contraindications
Hypersensitivity to vitamin D, its analogues, or any ingredient; hypercalcemia; evidence of vitamin D toxicity.
Warnings and precautions
Potent derivative; avoid additive effects with other vitamin D forms. Risk of severe hypercalcemia, vascular calcification, and nephrocalcinosis. Monitor serum calcium and phosphorus twice weekly.
Is CALCITRIOL in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by STERIMAX INC (Tier 3 shortage CALCITRIOL INJECTION USP" aria-label="Actual Tier 3 shortage CALCITRIOL INJECTION USP">CALCITRIOL INJECT), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A11CC04 CALCITRIOL. 6 of 14 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CALCITRIOL-ODAN | 0.25 MCG | CAPSULE | ODAN LABORATORIES LTD | MARKETED | DIN 02431637 |
| CALCITRIOL-ODAN | 0.5 MCG | CAPSULE | ODAN LABORATORIES LTD | MARKETED | DIN 02431645 |
| ROCALTROL | 0.25 MCG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00481823 |
| ROCALTROL | 0.5 MCG | CAPSULE | SEARCHLIGHT PHARMA INC | MARKETED | DIN 00481815 |
| TARO-CALCITRIOL | 0.25 MCG | CAPSULE | TARO PHARMACEUTICALS INC | MARKETED | DIN 02485710 |
| TARO-CALCITRIOL | 0.5 MCG | CAPSULE | TARO PHARMACEUTICALS INC | MARKETED | DIN 02485729 |
| CALCIJEX | 1 MCG | SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 00891738 |
| CALCIJEX | 2 MCG | SOLUTION | ABBVIE CORPORATION | CANCELLED POST MARKET | DIN 00891746 |
| CALCITRIOL INJECTION | 1 MCG | SOLUTION | FRESENIUS KABI CANADA LTD | CANCELLED POST MARKET | DIN 02245686 |
| CALCITRIOL INJECTION USP | 2 MCG | SOLUTION | STERIMAX INC | DORMANT | DIN 02399342 |
Who else supplies CALCITRIOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CALCITRIOL appears in 63 registered pack listings across 12 markets, published on 9 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This DIN is dormant — it holds a Health Canada authorization but is not currently being marketed in Canada, so it cannot simply be ordered from Canadian stock. Where a patient need exists, supply may be possible through exceptional importation or the Special Access Programme, subject to Health Canada's requirements and the prescriber's application. Nexara can advise on the route and on marketed alternatives.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.